High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma

作者: Katharina Bischof , Stian Knappskog , Ingunn Stefansson , Emmet Martin McCormack , Jone Trovik

DOI: 10.1186/S12885-018-4591-3

关键词:

摘要: Uterine serous carcinoma (USC) is a rare but aggressive subtype of endometrial carcinoma. Large-scale comprehensive efforts have resulted in an improved molecular understanding its pathogenesis, and the p53 pathway has been proposed as key player potentially targetable. Here we attempt to further portray USC by assessing isoform expression. We applied quantitative Real-Time PCRs (RT-qPCR) for expression analyses total mRNA well distinction p53β, p53γ, amino-terminal truncated Δ40p53 Δ133p53 retrospective cohort 37 patients with USC. TP53 mutation status was assessed targeted massive parallel sequencing. Findings were correlated clinical data. The landscape USCs heterogeneous dominated Δ133p53, while distinct p53β p53γ variants found at much lower levels. profiles varied between samples, their independent status. high relative be associated reduced progression-free survival (PFS). This first indication that elevated PFS single-center study may offer some insight USC, validation studies are crucial understand context-dependent tissue-specific role network gynecological cancer.

参考文章(33)
Kaori Fujita, Abdul M. Mondal, Izumi Horikawa, Giang H. Nguyen, Kensuke Kumamoto, Jane J. Sohn, Elise D. Bowman, Ewy A. Mathe, Aaron J. Schetter, Sharon R. Pine, Helen Ji, Borivoj Vojtesek, Jean-Christophe Bourdon, David P. Lane, Curtis C. Harris, p53 isoforms Δ133p53 and p53β are endogenous regulators of replicative cellular senescence Nature Cell Biology. ,vol. 11, pp. 1135- 1142 ,(2009) , 10.1038/NCB1928
Ingunn M. Stefansson, Maria Raeder, Elisabeth Wik, Monica Mannelqvist, Kanthida Kusonmano, Gøril Knutsvik, Ingfrid Haldorsen, Jone Trovik, Anne M. Øyan, Karl-H. Kalland, Anne Cathrine Staff, Helga B. Salvesen, Lars A. Akslen, Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer Oncotarget. ,vol. 6, pp. 10634- 10645 ,(2015) , 10.18632/ONCOTARGET.3521
G Hofstetter, A Berger, H Fiegl, N Slade, A Zorić, B Holzer, E Schuster, V J Mobus, D Reimer, G Daxenbichler, C Marth, A G Zeimet, N Concin, R Zeillinger, Alternative splicing of p53 and p73 : the novel p53 splice variant p53δ is an independent prognostic marker in ovarian cancer Oncogene. ,vol. 29, pp. 1997- 2004 ,(2010) , 10.1038/ONC.2009.482
Ran Brosh, Varda Rotter, When mutants gain new powers: news from the mutant p53 field Nature Reviews Cancer. ,vol. 9, pp. 701- 713 ,(2009) , 10.1038/NRC2693
Jonathan D Black, Diana P English, Dana M Roque, Alessandro D Santin, Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer Women's Health. ,vol. 10, pp. 45- 57 ,(2014) , 10.2217/WHE.13.72
V Marcel, K Fernandes, O Terrier, D P Lane, J-C Bourdon, Modulation of p53β and p53γ expression by regulating the alternative splicing of TP53 gene modifies cellular response. Cell Death & Differentiation. ,vol. 21, pp. 1377- 1387 ,(2014) , 10.1038/CDD.2014.73
Jean-Christophe Bourdon, Sylvanie Surget, Marie P. Khoury, Uncovering the role of p53 splice variants in human malignancy: a clinical perspective OncoTargets and Therapy. ,vol. 7, pp. 57- 68 ,(2013) , 10.2147/OTT.S53876
E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) European Journal of Cancer. ,vol. 45, pp. 228- 247 ,(2009) , 10.1016/J.EJCA.2008.10.026
James T Robinson, Helga Thorvaldsdóttir, Wendy Winckler, Mitchell Guttman, Eric S Lander, Gad Getz, Jill P Mesirov, Integrative genomics viewer Nature Biotechnology. ,vol. 29, pp. 24- 26 ,(2011) , 10.1038/NBT.1754